| Literature DB >> 7688884 |
B R Meisenberg1, A J Melaragno, R L Monroy.
Abstract
The authors describe the development of a clinical protocol to treat mustard gas-induced myelosuppression with granulocyte colony stimulating factor (G-CSF), a hematopoietic growth factor. Limited clinical evidence suggests a significant role for mustard gas-induced myelosuppression in the overall morbidity of mustard gas victims. Initial data from primates revealed that G-CSF could ameliorate neutropenia following nitrogen mustard exposure. Exploiting the extensive oncologic experience with G-CSF, which demonstrated its safety and absence of serious side effects the authors developed a clinical protocol for use of this drug in potential mustard gas victims in the Persian Gulf conflict.Entities:
Mesh:
Substances:
Year: 1993 PMID: 7688884
Source DB: PubMed Journal: Mil Med ISSN: 0026-4075 Impact factor: 1.437